These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38920591)
21. Protein kinase A inhibits lysophosphatidic acid induction of serum response factor via alterations in the actin cytoskeleton. Nguyen GH; French R; Radhakrishna H Cell Signal; 2004 Oct; 16(10):1141-51. PubMed ID: 15240009 [TBL] [Abstract][Full Text] [Related]
22. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer. Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603 [TBL] [Abstract][Full Text] [Related]
23. [Expression of lysophosphatidic acid receptor in human ovarian cancer cell lines 3AO, SKOV3, OVCAR3 and its significance]. Wang P; Wu XH; Chen WX; Shan BE; Guo Q Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1422-4, 1431. PubMed ID: 16305971 [TBL] [Abstract][Full Text] [Related]
24. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. Meng Y; Kang S; Fishman DA FEBS Lett; 2005 Feb; 579(5):1311-9. PubMed ID: 15710431 [TBL] [Abstract][Full Text] [Related]
25. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer. Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis. Lu Z; Chen Y; Hu Z; Hu C Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018 [TBL] [Abstract][Full Text] [Related]
27. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410 [TBL] [Abstract][Full Text] [Related]
29. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. Hu YL; Albanese C; Pestell RG; Jaffe RB J Natl Cancer Inst; 2003 May; 95(10):733-40. PubMed ID: 12759391 [TBL] [Abstract][Full Text] [Related]
30. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. Murph MM; Liu W; Yu S; Lu Y; Hall H; Hennessy BT; Lahad J; Schaner M; Helland A; Kristensen G; Børresen-Dale AL; Mills GB PLoS One; 2009; 4(5):e5583. PubMed ID: 19440550 [TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells. Jeon ES; Heo SC; Lee IH; Choi YJ; Park JH; Choi KU; Park DY; Suh DS; Yoon MS; Kim JH Exp Mol Med; 2010 Apr; 42(4):280-93. PubMed ID: 20177148 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458 [TBL] [Abstract][Full Text] [Related]
33. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Jeon ES; Moon HJ; Lee MJ; Song HY; Kim YM; Cho M; Suh DS; Yoon MS; Chang CL; Jung JS; Kim JH Stem Cells; 2008 Mar; 26(3):789-97. PubMed ID: 18065393 [TBL] [Abstract][Full Text] [Related]
34. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220 [TBL] [Abstract][Full Text] [Related]
35. Lysophosphatidic acid signaling in ovarian cancer. Jesionowska A; Cecerska-Heryc E; Matoszka N; Dolegowska B J Recept Signal Transduct Res; 2015; 35(6):578-84. PubMed ID: 26393967 [TBL] [Abstract][Full Text] [Related]
36. Methods for quantifying lysophosphatidic acid in body fluids: a review. Jesionowska A; Cecerska E; Dolegowska B Anal Biochem; 2014 May; 453():38-43. PubMed ID: 24613261 [TBL] [Abstract][Full Text] [Related]
37. Lysophosphatidic Acid Promotes Epithelial to Mesenchymal Transition in Ovarian Cancer Cells by Repressing SIRT1. Ray U; Roy SS; Chowdhury SR Cell Physiol Biochem; 2017; 41(2):795-805. PubMed ID: 28214851 [TBL] [Abstract][Full Text] [Related]
38. Role of the 18:1 lysophosphatidic acid-ovarian cancer immunoreactive antigen domain containing 1 (OCIAD1)-integrin axis in generating late-stage ovarian cancer. Wang C; Michener CM; Belinson JL; Vaziri S; Ganapathi R; Sengupta S Mol Cancer Ther; 2010 Jun; 9(6):1709-18. PubMed ID: 20515946 [TBL] [Abstract][Full Text] [Related]
39. Production and application of LPA polyclonal antibody. Chen JH; Zou F; Wang ND; Xie SW; Zhang X Bioorg Med Chem Lett; 2000 Aug; 10(15):1691-3. PubMed ID: 10937726 [TBL] [Abstract][Full Text] [Related]
40. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]